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ABSTRACT 
BACKGROUND	 Cardiac	 surgery	 with	 cardiopulmonary	 bypass	 impairs	 hemostasis	 due	 to	hemodilution	and	consumption	of	platelets	and	coagulation	factors,	such	as	fibrinogen.		The	aim	of	this	thesis	was	to	study	the	role	of	fibrinogen	in	bleeding	complications	in	cardiac	surgery	patients.		
METHODOLOGY	Patients	who	underwent	cardiac	surgery	at	Sahlgrenska	University	Hospital	from	2009	to	2017	were	included	in	four	studies..	Study	I	assessed	the	importance	of	preoperative	plasma	fibrinogen	concentration	 for	excessive	bleeding	 and	 the	need	 for	 red	 blood	cell	 transfusion	 in	an	observational	study	in	1954	patients.	Study	II	was	a	double-blinded	placebo-controlled	study	where	48	patients	were	randomized	to	prophylactic	administration	of	fibrinogen	concentrate	or	placebo.	Primary	endpoint	was	postoperative	bleeding	volume.	Study	III	was	an	observational	study		in	5408	patients	 that	 assessed	 if	 patients	who	 had	 received	 perioperative	 fibrinogen	 concentrate	 due	 to	bleeding	had	a	higher	risk	of	thromboembolic	complications	or	death.	Study	IV	was	an	in	vitro	study	where	 fibrinogen	 concentrate	 was	 added	 to	 blood	 samples	 from	 15	 patients	 to	 investigate	 if		concomitant	tranexamic	acid	and	fibrinogen	administration	has	additional	effects	on	clot	formation	compared	to	fibrinogen	alone.		
RESULTS	 The	 preoperative	 plasma	 fibrinogen	 concentration	 correlated	 inversely	 to	 increased	postoperative	 bleeding	 but	 not	 to	 RBC	 transfusion.	 Prophylactic	 infusion	 of	 2	 g	 fibrinogen	concentrate	 did	 not	 reduce	 postoperative	 bleeding	 volume.	 Patients	 who	 received	 fibrinogen	concentrate	 due	 to	 perioperative	 bleeding	 did	 not	 have	 a	 higher	 risk	 of	 thromboembolic	complications	or	death	during	the	first	year	after	surgery.	The	combination	of	tranexamic	acid	and	fibrinogen	did	not	have	additional	effects	on	platelet-independent	clotting	time	or	clot	firmness	than	fibrinogen	alone.		
CONCLUSION	Preoperative	plasma	fibrinogen	concentration	is	associated	with	excessive	bleeding	after	 cardiac	 surgery.	 Preoperative	 supplementation	 with	 fibrinogen	 concentrate	 did	 not	significantly	 influence	 postoperative	 bleeding	 in	 low	 risk	 patients	 undergoing	 coronary	 artery	bypass		grafting.	Perioperative	administration	of	fibrinogen	concentrate	in	case	of	bleeding	appears	safe.	The	enhancing	effects	of	fibrinogen		concentrate	on	clot	firmness	in	blood	samples	from	cardiac	surgery	patients	was	not	further	increased	in	the	presence	of	tranexamic	acid.		
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POPULÄRVETENSKAPLIG 
SAMMANFATTNING Hjärtats	 och	 lungornas	 funktioner	 kan,	 vid	 behov,	 till	 exempel	 under	hjärtoperationer,	 tas	 över	 av	 en	 så	 kallad	 hjärt-lungmaskin.	 I	 hjärt-lungmaskinen	pumpas	blodet	förbi	hjärtat	samtidigt	som	det	syresätts.	Hjärtat	kan	då	tillfälligt	stoppas	utan	att	patientens	liv	hotas.	En	nackdel	vid	användandet	av	hjärt-lungmaskin	är	att	blodets	förmåga	att	stoppa	blödning	och	samtidigt	motverka	blodproppar	påverkas	negativt.	Blodets	 förmåga	 att	 balansera	 blödning	 och	 proppbildning	 kallas	 för	hemostas.	Hemostasen	under	och	efter	hjärtkirurgi	påverkas	av	flera	fak-torer	 relaterade	 till	 både	 patienten,	 som	 till	 exempel	 ålder	 och	 övrig	sjuklighet,	samt	till	vilken	typ	av	kirurgisk	metod	som	används	och	hur	lång	tid	operationen	tar.	När	man	använder	en	hjärt-lungmaskin	måste	patientens	blod	spädas	ut	och	blodet	utsätts	också	för	kroppsfrämmande	ytor,	 bland	 annat	 plastslangar.	 Detta	 drar	 igång	 en	 aktivering	 och	förbrukning	 av	 koagulationsfaktorer	 samt	 en	 aktivering	 av	inflammatoriska	 reaktioner.	 Denna	 påverkan	 på	 koagulationssystemet	kan	orsaka	allvarlig	blödning	både	under		 och	 efter	 kirurgi	 och	 en	del	patienter	kan	behöva	opereras	på	nytt	på	grund	av	dessa	blödningar.		Ungefär	 hälften	 av	 de	 hjärtkirurgiska	 patienterna	 behöver	 behandlas	med	blodtransfusion.	En	akut	operation	på	grund	av	blödning	innebär	en	ökad	risk	för	sjuklighet	och	död	efter	hjärtkirurgi.	Det	är	därför	viktigt	att	kunna	förutse	och	minska	dessa	blödningskomplikationer.	Fibrinogen	är	den	koagulationsfaktor	som	finns	i	störst	mängd	i	blodet.	Fibrinogen	är	ett	 protein	 som	 vid	 aktivering	 bildar	 ett	 nät	där	 blodplättar	 och	 röda	blodkroppar	fastnar	och	därmed	bildas	ett	koagel	på	platsen	för	skadan.	Vid	 större	 blödning	 förbrukas	 tillgängligt	 fibrinogen	 och	 därför	 har	fibrinogenkoncentrat	 under	 de	 senare	 åren	 använts	 allt	 oftare	 för	 att	förbättra	 koagulationen	 under	 och	 efter	 operationen.		Fibrinogenkoncentrat	tillverkas	av	plasma	från	blodgivare.	Syftet	med	 avhandlingsarbetet	 är	 att	 belysa	 fibrinogenets	 roll	 när	 det	gäller	 att	 förutse	 blödning,	 om	 profylaktisk	 behandling	 med	 fibrino-genkoncentrat	före	operationen	minskar	blödning,	om	behandling	med	fibrinogen	till	blödande	patienter	är	säker	och	om	fibrinogen	tillsammans	med	standardbehandling	med	läkemedel	som	hämmar	blodkoaglets	ned-brytning,	så	kallad	fibrinolyshämmare,	ger	förbättrad	koagulation.	
	I	delarbete	I	undersöktes	om	det	fanns	ett	samband	mellan	patienternas	fibrinogenkoncentration	 i	 blodet	 före	 operationen	 och	 mängden	blödning	efter	operationen	samt	behovet	av	blodtransfusion.	Vi	fann	att	patienter	med		låg	fibrinogenkoncentration	hade	en	signifikant	ökad	risk	för	 allvarlig	blödning.	Däremot	 sågs	 inget	samband	mellan	 fibrinogen-koncentration	och	behovet	av	blodtransfusioner.	Delarbete	II	syftade	till	att	undersöka	om	förebyggande	behandling	med	fibrinogenkoncentrat	innan	kirurgi	kan	bidra	till	att	minska	blödnings-mängden	efter	operationen.	Patienterna	delades	in	i	två	grupper	där	den	ena	gruppen	behandlades	med	fibrinogenkoncentrat	och	den	andra	med	placebo.	Studien	kunde	inte	visa	att	förebyggande	infusion	av	fibrinogen-koncentrat	minskar	blödningsmängden	efter	kranskärlsoperationer.	I	delarbete	III	studerades	5408	patienter	som	hjärtopererats.	Vi	jämförde	de	 patienter	 som	 erhållit	 fibrinogenkoncentrat	 på	 grund	 av	 blödning	under	 eller	 efter	 hjärtoperationen	med	 de	 patienter	 som	 inte	 erhållit	detta.	 Jämförelsen	 gjordes	med	 avseende	 på	 risk	 att	 drabbas	 av	 blod-proppar	och	död.	Patienter	som	erhållit	fibrinogenkoncentrat	hade	inte	en	högre	risk	för	blodproppar	och	död	upp	till	ett	år	efter	kirurgi.		Delarbete	 IV	 var	 en	 experimentell	 studie	 som	 beskriver	 effekten	 av	fibrinogentillsats	till	blodprover	som	tagits	från	hjärtkirurgiska	patienter	före	 och	 efter	 infusion	 av	 tranexamsyra.	 Tranexamsyra	 är	 en	 fibrino-lyshämmare,	det	vill	säga	ett	läkemedel	som	förhindrar	nedbrytning	av	blodkoagel	 och	 därmed	minskar	 blödningar.	 Tranexamsyra	 ges	 rutin-mässigt	till	patienter	som	hjärtopereras.	I	studien	förbättrade	fibrinogen-tillsats	 koagelbildning	 och	 koagelstyrka	 i	 blodproverna,	 men	 effekten	skiljde	sig	inte	i	blodprover	som	samlats	före	eller	efter	att	tranexamsyra	givits.		Sammanfattningsvis	har	patienter	med	låg	koncentration	av	fibrinogen	i	blodet	 en	 ökad	 risk	 för	 allvarlig	 blödning	 efter	 hjärtkirurgi.	 Att	 före-byggande	ge	fibrinogenkoncentrat	till	patienter	med	normala	fibrinogen-nivåer	 och	 låg	 förväntad	 risk	 för	 blödning	 minskade	 ej	 signifikant	blödningsmängden	när	de	genomgick	kranskärlskirurgi.	Användandet	av	fibrinogenkoncentrat	 till	patienter	med	pågående	blödning	 i	avsikt	 att	förbättra	 koagulationen	 förefaller	 sig	 säkert	 och	 ökar	 inte	 risken	 för	blodproppar.	 Den	 förstärkta	 koagelstyrkan	 som	 fibrinogenkoncentrat	bidrar	till	i	blodprover	från	hjärtkirurgiska	patienter	blir	inte	ytterligare	förbättrad	i	närvaro	av	fibrinolyshämmare.
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1 INTRODUCTION Excessive	bleeding	is	common	during	and	after	cardiac	surgery.	It	can	be	caused	both	by	the	surgical	trauma	and	by	an	impaired	hemostasis.	It	is	of	great	importance	to	address	the	causes	to	reduce	complications	related	to	bleeding.	 The	 coagulation	 factor	 fibrinogen	 is	 the	 substrate	 in	 the	coagulation	system	with	the	highest	plasma	concentration	and	essential	in	blood	clot	 formation.	However,	 there	 is	 limited	knowledge	about	the	role	of	fibrinogen	to	predict	and	prevent	bleeding	in	cardiac	surgery.		
1.1 OVERVIEW OF THE HEMOSTASIS AND 
THE COAGULATION SYSTEM In	 the	presence	of	a	vascular	 injury,	 there	 is	an	immediate	response	by	smooth	muscle	cells	in	the	vessel	wall,	initiated	by	sympathetic	receptors.	This	 	causes	a	vasoconstriction	at	the	site	of	 injury,	 reducing	 the	blood	flow	through	the	injured	area.	In	the	damaged	vessel,	subendothelial	cells	and	collagen	are	exposed	to	plasma.	The	von	Willebrand	factor	(vWF),	a	protein	circulating	in	plasma,	binds	to	receptors	on	the	exposed	collagen.	Further	 on,	 vWF	 attracts	 platelets	 to	 the	 site,	 which	 connects	 to	 vWF	through	 receptors	 (Ib)	 on	 their	 surface.	 This	 activates	 the	 platelets,	making	them	change	shape		and	stimulates	to	degranulation.	The	release	of	adenosine	diphosphate	(ADP),	calcium	(Ca)	 thromboxane	A2	(TXA2)	and	 thrombin	 promotes	 attraction,	 activation	 and	 adhesion	 of	 more	platelets.	Additional	vWF,	fibrinogen	and	coagulation	factor	V	and	XIII	are		also	released.	Fibrinogen,	readily	circulating	in	plasma	and	released	from	platelets,	binds	to	activated	glycoprotein	receptor	IIb/IIIa	(GPIIb/IIIa)	on	the	platelet	surface	,	forming	a	rather	weak	plug		(1-3).		At	 the	 site	 of	 injury	 tissue	 factor	 (TF),	 a	 glycoprotein,	 expressed	 by	subendothelial	and	perivascular	 cells	 is	 exposed.	TF	 and	 its	 interaction	with	circulating	coagulating	factor	VII	in	plasma,	initiate	a	chain	reaction	that	activates	several	other	coagulation	factors.	These	coagulation	factors	interact	with	activated	platelets	and	forms	a	complex	both	attached	to	the	vessel	wall	and	directly	to	the	platelets.	The	product	of	this	cascade	is	an	extensive	 conversion	 of	 prothrombin	 to	 thrombin.	 	 Thrombin	 cleaves	fibrinogen	to	 fibrin,	as	well	as	activates	 factor	XIII.	Together,	 fibrin	and	factor	XIII,	 form	a	 stable	network	 and	a	mature	blood	 clot	 is	 achieved.	
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During	this	process,	circulating	red	blood	cells	(RBCs)	are	trapped	in	the	clot	(1,	4,	5).		
Figure	1. Illustration	of	the	coagulation	cascade	where	the	end	product	is	an	
insoluble	fibrin	clot.	Image	with	the	courtesy	of	Aleksandra	Antovic,	Dept.	of	
Medicine,	Karolinska	Institute.		
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Figure	2. Colorized	scanning	electron	micrograph	of	a	whole	blood	clot.	Fibrin	
strands	in	green,	platelets	in	purple	and	red	blood	cells	(RBCs)		in	red.		Image	with	
the	courtesy	of		Yuri	Veklich	and	John	W		Weisel,	Dept.	of	Cell	and	Developmental	
Biology,	Perelman	School	of	Medicine,	University	of	Pennsylvania.	
	
1.2 FIBRINOGEN The	glycoprotein	fibrinogen	is	also	known	as	coagulation	factor	I.	It	was	discovered	over	350	years	ago	when	Malphigi	in	1666	describes	the	fibrin	strands	 in	 a	 microscope.	 During	 the	 19th	 century,	 Virchow	 named	 the	protein	fibrinogen	and	later	in	the	19th	century,	Hammarsten	was	able	to	purify	it	(6).		Fibrinogen	has	a	molecular	weight	of	340	kilodalton	(kDa)	and	is	a	key	factor	 in	 the	 human	 coagulation	 system	 (7).	 Approximately	 2-5	 g	 of	fibrinogen	 is	synthesized	daily	 the	by	 the	hepatic	cells	 in	 the	 liver.	The	same	 quantity	 is	 catabolized	 through	 normal	 protein	 degradation,	 the	coagulation	process	and	other	unidentified	pathways	(8).	Fibrinogen	has	an	estimated	half	time	of	three	to	four	days	(9).	The	plasma	concentration	in	 healthy	 humans	 is	 approximately	 1.8-4.5	 g/L	 depending	 on	measurement	 device	 and	 reagent	 (8,	 10).	 The	 concentration	 is	 usually	determined	 by	 the	 Clauss	method	which	measures	 coagulation	 time	 in	diluted	plasma	in	the	presence	of	excess	thrombin,	an	environment	where	
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the	 amount	 of	 fibrinogen	 is	 the	 limiting	 factor	 and	 coagulation	 time	 is	inversely	proportional	to	fibrinogen	concentration	(11,	12).		Fibrinogen	 is	 a	 physiological	 substrate	 for	 thrombin,	 factor	 XIII	 and	plasmin.	A	fibrinogen	molecule	is	a	dimer	containing	pairs	of	chains	linked	together	with	disulfide	bridges.	These	 chains	 are	 cleaved	by	 thrombin,	thus	 releasing	 fibrinopeptides	 from	 the	 terminals,	 forming	 fibrin.	 The	fibrin	molecules	begin	to	assemble	to	form	fibrin	polymers.	These	fibrin	polymers	are	further	crosslinked	and	stabilized	by	activated	factor	XIII,	forming	 branched	 fibrin	 fibers	 (13,	 14).	 The	 fibrin	 clot	 is	 degraded	 by	plasmin.	 As	 mentioned	 above,	 fibrinogen	 also	 supports	 platelet	aggregation	 in	 primary	 hemostasis	 by	 acting	 as	 a	 ligand	 to	 GPIIb/IIIa,	which	is	expressed	on	the	surface	of	activated	platelets	(14).			
Figure	3. Schematic	illustration	of	a	fibrinogen	molecule.		
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Figure	4. Schematic	illustration	of	fibrin	assembling.	Upon	fibrinogen	peptide	
cleavage	by	thrombin,	fibrin	monomers		assemble	to	form	fibrin	polymers.		During	
this		process,		activated	FXIII	stabilizes		peptide	bond	formation	between	the	fibrin	
polymers,	forming	branched,	crosslinked,	stable	fibrin	fibres.	Besides	 its	hemostatic	effect,	 fibrinogen	 is	an	acute	phase	reactant	and	regulates	 inflammatory	 responses	(15).	 Fibrinogen	and	 its	degradation	products	have	multiple	receptors	which	interact	with	and	activate	a	wide	range	of	immune	cells,	both	in	the	blood	stream	and	in	the	perivascular	space	(15).	Fibrinogen	plasma	levels	are	normally	elevated	with	age,	 in	females	 and	 	 during	 pregnancy	 and	 are	 also	 associated	 with	 lifestyle	factors	 such	 as	 tobacco-	 and	 alcohol	 use	 (16).	 Epidemiological	 studies	have	 shown	 a	 strong	 association	 between	 elevated	 fibrinogen	
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concentration	and	the	risk	of	major	cardiovascular	disease	and	mortality,	but	a	causal	relationship	has	not	been	established	(16,	17).			
Hypofibrinogenemia The	presence	of	low	levels	of	circulating	fibrinogen,	hypofibrinogenemia,	may	 have	 different	 causes.	 Acquired	 hypofibrinogenemia	 is	 most	frequently	caused	by	consumption	of	clotting	factors	due	to	bleeding	and	in	cases	of	hemodilution.	It	may	also	be	present	in	patients	with	reduced	synthesis	due	to	hepatic	failure	as	well	as	in	acute	leukemia	(18).		In	major	hemorrhage,	fibrinogen	is	one	of	the	coagulation	factors	that	first	fall	 to	 critical	 levels,	 since	 the	 increase	 in	 synthesis	 rate	 is	most	 often	insufficient	 to	 compensate	 the	 use	 and	 breakdown	 of	 the	 coagulation	factor	 (19-21).	 Further	 on,	 acidosis	 and	 hypothermia	 that	 accompany	massive	 bleeding,	 induce	 coagulopathy	 and	 seem	 to	 aggravate	 an	increased	breakdown	and	decreased	synthesis	of	the	coagulation	factor	(22).	Hemodilution	due	to	volume	resuscitation	further	reduces	available	fibrinogen	in	plasma,	causing	reduced	clot	stability	(23,	24).	Bleeding	and	hypofibrinogenemia	seem	to	be	related	to	both	increased	morbidity	and	mortality	in	both	trauma	and	in	the	postoperative	setting	(25-27).	Congenital	 disorders	 of	 fibrinogen	 are	 rare.	 It	 can	 present	 as		hypofibrinogenemia,	 dysfibrinogenemia	 and	 afibrinogenemia	 and	 the	severity	 of	 symptoms	 is	 dependent	 upon	 the	 level	 of	 dysfunction	 or	deficiency	of	fibrinogen.	It	can	be	as	little	as	no	symptoms	at	all	to	fatal	hemorrhages	(28).	Major	and	spontaneous		bleeding	is	generally	reported	in	patients	with	hypofibrinogenemia	and	a	plasma	level	below	0.5	g/L	and	patients	with	a	level	over	1	g/L	do	not	generally	experience	unprovoked	bleeds	(29,	30).	Contractively,	the	incidence	of	both	venous	and	arterial	thrombosis	among	these	patients	is	elevated.	The	reason	is	not	completely	understood,	 but	 seems	 to	 be	 a	 cause	 of	 excess	 thrombin	 generated	 in	absence	 of	 fibrinogen.	 The	 thrombin	 is	 instead	 available	 for	 platelet	activation	and	aggregation,	leading	to	a	large	and	loosely	packed	platelet	thrombus	(31-33).		
Treatment of hypofibrinogenemia There	 are	 three	 different	 ways	 to	 administer	 fibrinogen:	 plasma,	cryoprecipitate	 and	 fibrinogen	 concentrate.	 Plasma	 for	 transfusions	contains	 about	 1-3	 g	 fibrinogen	 per	 litre.	 Large	 doses	 are	 therefore	
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required	to	restore	a	fibrinogen	deficit	and	supplementation	with	plasma	is	often	accompanied	by	a	risk	of	hypervolemia	(34).	If	the	target	level	of	fibrinogen	concentration	is	higher	than	that	of	the	administered	plasma,	it	cannot	be	reached	(35,	36).	Cryoprecipitate	is	produced	from	plasma	by	precipitating	 the	coagulation	 factors	FVIII,	vWF	and	 fibrinogen	by	 their	weight.	The	concentration	of	fibrinogen	in	cryoprecipitate	is	about	16	g/L		(27).	Since	the	product	is	constituted	by	plasma	from	multiple	donors	and	does	 not	 undergo	 any	 antiviral	 processing,	 it	 has	 been	 withdrawn	 for	safety	concerns	in	several	European	countries,	but	is	still	widely	used	in	the	United	States	and	in	the	United	Kingdom	(37).	Pasteurized	fibrinogen	concentrate	is	derived	from	human	plasma	and	is	delivered	as	a	freeze-dried	 powder	 and	 dissolved	 to	 a	 concentration	 of	 about	 20	 g/L.	Fibrinogen	is	processed	through	viral	inactivation	processes,	which	also	remove	antigens	and	antibodies	that	reduce	the	risk	of	immunological	and	allergic	 reactions	 (38).	 Fibrinogen	 concentrate	 has	 been	 commercially	available	 since	 the	 1960’s	 for	 prophylaxis	 and	 treatment	 of	 bleeding	episodes	 in	patients	with	congenital	hypo-	or	afibrinogenemia.	 In	 these	patients,	 supplementation	 is	usually	made	below	1	g/L,	since	 this	 level	seems	 to	 be	 sufficient	 to	 keep	 hemostasis	 when	 no	 other	 coagulation	deficiency	is	present	(31).			In	 recent	 years,	 infusion	 of	 fibrinogen	 concentrate	 has	 become	 an	established	method	to	treat	patients	with	ongoing	bleeding	after	surgery	and	trauma	(39,	40).	For	decades,	a	plasma	concentration	of	above	1g/L	was	considered	to	be	enough	for	effective	clot	formation	and	maintaining	hemostasis	 even	 in	 patients	with	 acquired	 hypofibrinogenemia	 due	 to	bleeding(19,	41).	However,	 in	situations	of	major	bleeding,	more	recent	data	suggests	that	a	higher	plasma	concentration	of	fibrinogen	and	a	more	liberal	 use	 of	 fibrinogen	 concentrate	 might	 be	 desirable	 to	 restore	 or	improve	hemostasis	(35,	42,	43).				
1.3 CARDIAC SURGERY In	the	late	19th	century,	the	first	reported	successful	suture	on	a	human	heart	 was	 reported	 (44).	 The	 gained	 knowledge	 of	 the	 importance	 of	sterile	 technique	 and	 development	 of	 anesthesia	 helped	 to	 make	 the	procedure	 successful	 (44).	 In	 the	 1950’s,	 the	 development	 of	 the	cardiopulmonary	bypass	(CPB),	i.e.	heart-lung	machine,	together	with	the	start	of	commercial	manufacture	of	the	anticoagulant	heparin	paved	the	way	 for	 open	 heart	 surgery.	 CPB	 and	 anticoagulation	 with	 heparin	
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facilitated	extracorporeal	circuits	without	deleterious	clot	formation	and	thereby	 the	 “modern”	 cardiac	 surgery	 was	 born	 (45).	 Since	 then,	 the	development	of	techniques	has	made	it	possible	to	perform	surgery	on	e.g.	valves,	coronary	arteries		and	complex	congenital	heart	defects.		The	use	of	CPB	provides	a	bloodless	field	during	cardiac	surgery.	The	CPB	circuit	 consists	 of	 pumps,	 tubing,	 cannulas,	 reservoir,	 oxygenator,	 heat	exchanger	and	an	arterial	line	filter,	described	in	Figure	5.		
Figure	5. The	CPB	circuit.	Venous	blood	is	drained	either	from	the	right	atrium	or	
from	v.	cava	superior	and	inferior.		Through	gravity,	the	venous	blood	drains		into	
a	reservoir.	The	roller	pump	moves	blood	from	the	reservoir,	through	a	heat	
exchanger	to	an	oxygenator.	After	oxygenation,	the	blood	returns	to	the	arterial	
circulation	through	a	cannula	in	the	aorta.		In	 2017,	 5800	 open	 cardiac	 surgery	 procedures	 were	 performed	 in	Sweden,	compared	to	nearly	9400	in	the	early	1990’s	(46).	The	decline	in	the	number	of	procedures	is	largely	due	to	the	progress	of	endovascular	treatment	by	percutaneous	coronary	interventions	(PCI)	in	patients	with	coronary	artery	disease.	Despite	 this,	 cardiac	surgery	as	a	 treatment	of	coronary	artery	disease	and	valvular	disease	is	still	a	needed	intervention	in	selected	patients	with	more	complicated	disease.	The	number	of	open	heart	surgery	has	been	fairly	constant	since	2013.	Coronary	artery	bypass	grafting	(CABG)	accounts	for	45%,	isolated	valve	surgery	for	25%	and	a	combined	 CABG	and	 valve	 surgery	 for	9%	 of	 all	 cardiac	procedures	 in	Sweden	(46).		The	30-day	mortality	is	about	2.5%	after	cardiac	surgery	(46).	There	are	still	 substantial	 risks	 of	 complications	 after	 cardiac	 surgery	 such	 as	bleeding,	stroke,	renal	and	heart	failure	as	well	as	pulmonary	dysfunction	(47-54).		
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Cardiac surgery and bleeding Postoperatively,	 the	 bleeding	 volume	 is	 measured	 using	 chest	 tubes,	inserted	 in	 the	 pleura	 and	 pericardium	 at	 the	 end	 of	 surgery.	Postoperatively,	a	cardiac	surgery	patient	may	be	expected	to	bleed	about	500-1000	 ml.	 The	 drainage	 is	 usually	 removed	 the	 day	 after	 surgery.	Bleeding	can	be	caused	by	the	surgical	trauma,	 impaired	hemostasis	or	both.	Hemostasis	during	and	after	surgery	is	influenced	by	several	factors,	some	of	which	are	patient	related,	while	others	are	related	to	the	surgical	procedure.	The	use	of	CPB	induces	activation	of	the	hemostatic	system,	mostly	 because	 of	 the	 contact	 between	 the	 patient’s	 blood	 and	 the	artificial	surfaces	of	the	circuit.	This	leads	to	enhanced	platelet	activation,	increased	fibrinolysis	and	substantial	inflammatory	response	interacting	with	the	coagulation	system	(55,	56).	The	required	hemodilution	further	lowers	 the	 concentration	 of	 coagulation	 factors	 (57,	 58).	 Preoperative	medication	 with	 anticoagulants	 and	 antiplatelet	 therapy	 may	 also	contribute	to	the	compromised	hemostasis	(59).		
Figure	6. Overview	of	factors	causing	postoperative	bleeding	in	cardiac	surgery.		
Factors	involve	the	surgical	trauma,		impaired	hemostasis	or	both.			 	
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Despite	progress	in	surgical	techniques	and	the	gained	understanding	of	factors	affecting	perioperative	hemostasis,	approximately	one	in	twenty	patients	is	still	in	need	of	re-exploration	due	to	bleeding	(46,	60),	where	a	surgical	cause	of	bleeding	is	found	in	60-80%	of	the	cases(60,	61).	This	leaves	 a	 substantial	 fraction	 of	 patients	 with	 bleeding	 due	 to	coagulopathy,	 where	 surgical	 intervention	 may	 be	 avoided	 if	 effective	countermeasures	 are	 initiated.	 Re-exploration	 for	 bleeding	 is	 an	independent	 risk	 factor	 for	 increased	 morbidity	 and	 mortality	 after	cardiac	surgery	and	data	suggest	a	two	to	threefold	increase	in	the	risk	of	death	after	re-exploration	(62,	63).	Major	bleeding	 in	itself	and	the	 	 re-operation	 due	 to	 bleeding	 increase	 the	 risks	 of	 renal	 failure	 and	arrythmias,	 as	 well	 as	 the	 risk	 of	 prolonged	 ventilatory	 support	 and	prolonged	stay	at	the	intensive	care	unit	(64-66).			
Blood transfusions in cardiac surgery Transfusion	of	blood	products	is	common	 in	cardiac	surgery	where	 the	use	in	case	of	severe	bleeding	is	lifesaving.	However,	blood	transfusions	may	involve	undesirable	adverse	effects.	Today,	the	risk	of	transmission	of	 infectious	 agents	 is	 low,	 but	 cannot	 be	 completely	 ignored.	Immunologic	 reactions	 of	 varying	 degree,	 such	 as	 hemolysis	 and	anaphylaxis	 as	 well	 as	 transfusion	 related	 lung	 injury	 (TRALI)	 and	transfusion	associated	circulatory	overload	(TACO)	are	detrimental	side	effects.	 Fatal	 reactions	 are	 rare,	 occurring	 in	 about	 one	 in	 200	 000-400	000	transfused	units	(67).	When	stored	in	a	blood	bank,	the	cells	do	change	 properties.	 After	 a	 few	 days,	 red	 blood	 cells	 gradually	 lose	 the	ability	to	bind,	transport	and	deliver	oxygen	to	the	tissues,	mostly	due	to	a	 reduction	 in	 2,3-diphosphoglycerate	 (2,3-DPG)	 and	 altered	deformability	 (68).	The	 clinical	 implications	of	 these	 so	 called	 “storage	lesions”	 are	 debated,	where	 older	 RBC’s	 have	 been	 suggested	 to	 cause	more	harm	than	fresh	ones	(69).	However,	recent	studies	have	not	been	able	 to	 find	 associations	 between	 length	 of	 storage	 of	 the	 RBCs	 and	mortality,	nor	any	increased	risk	of	adverse	events	such	as	renal	failure,	infections,	 stroke,	 embolisms,	 thrombosis	 or	 respiratory	 failure	 as	previously	described	(70,	71).			The	prevalence	of	 transfusions	differs	extensively	between	 institutions	and	reported	transfusion	rates	do	vary	between	10-85%	(72,	73)	but	are	usually	 around	 50-60%.	 	 Most	 of	 the	 transfused	 blood	 products	 are	allocated	to	about	one	fifth	of	the	patients,	receiving	massive	transfusions	
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(74).	Recognized	risk	factors	for	the	need	of	allogenic	blood	transfusion	in	cardiac	surgery	are	preoperative	anemia,	the	need	for	re-sternotomy	or	acute	surgery,	low	body	mass	index,	higher	age	and	preoperative	use	of	drugs	 affecting	 hemostasis	 (74).	 Since	 avoidance	 of	 unnecessary	transfusions	is	of	high	priority,	not	only	due	to	undesireble	side	effects,	but	 also	 has	 health	 economic	 benefits,	 determining	 safe	 thresholds	 for	transfusion	is	crucial.		In	observational	retrospective	studies,	transfusion	of	 blood	 products	 have	 been	 associated	 with	 poor	 outcome	 and	reductions	 of	 avoidable	 transfusions	 during	 and	 after	 cardiac	 surgery	have	been	suggested	to	reduce	both	morbidity	and	mortality	(75-77).	On	the	contrary,	recent	data	from	two	large	randomized	studies	of	restrictive	versus	 liberal	 transfusion	 strategies	 after	 cardiac	 surgery	 did	 not	establish	 any	 difference	 in	 their	 primary	 outcome	 regardless	 of	transfusion	approach	(78,	79),	although	older	patients	(>75	years)	seem	to	benefit	from	a	more	restrictive	strategy	(78).			
Treatment with antifibrinolytics in cardiac surgery The	use	of	anti-fibrinolytic	drugs	is	widespread	in	cardiac	surgery,	since	they	 have	 been	 shown	 to	 significantly	 reduce	 blood	 loss	 and	 allogenic	blood	 transfusion	 (80).	 The	 use	 also	 seems	 to	 lower	 the	 rate	 of	 re-operations	due	to	bleeding		(81).	A	causal	relationship	between	the	use	of	antifibrinolytics	and	mortality	has	not	been	established.	At	our	institution,	tranexamic	 acid	 (TXA)	 is	 used	 as	 a	 routine	 pre-	 and	 post-CPB.	 TXA	 is	usually	well	tolerated,	and	has	a	low	incidence	of	side	effects,	 including	thromboembolic	complications	(80,	81).		TXA	 prevents	 the	 activation	 of	 plasminogen	 to	 plasmin	 (82).	Consequently,	 the	degradation	of	 fibrin	 clots	 is	 inhibited,	 Figure	7.	The	action	is	mainly	competitive,	but	can	be	non-competitive	with	high	doses.	The	inhibition	of	plasmin	generation	and	activation	also	seem	to	reduce	plasmin	 induced	 platelet	 activation	 during	 CPB	 (83,	 84).	 Patients	receiving	 TXA	 perioperatively	 appear	 to	 have	 a	 lower	 grade	 of	inflammatory	 response	 postoperatively,	 which	 may	 be	 a	 result	 from	reduced	fibrinolysis.	During	CPB,	a	reduced	fibrinolysis	leads	to	a	lower	plasmin	 activity	 along	 with	 attenuated	 plasmin	 activated	 pro	inflammatory	cytokines	and	complement	proteins	(85-87).	Furthermore,	TXA	 may	 partly	 improve	 platelet	 aggregation	 in	 patients	 treated	 with	acetyl	 salicylic	 acid	 and	 clopidogrel	 due	 to	 a	 mechanism	 not	 yet	established	(88).		
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Figure	7. In	the	fibrinolytic	process,	fibrin	is	degraded	by	plasmin.	TXA	inhibits	the	
activation	of	plasminogen	to	plasmin,	thus	inhibiting	fibrinolysis.		
	
Thromboelastometry in cardiac surgery In	 the	 case	 of	 substantial	 perioperative	 bleeding,	 it	 is	 important	 to	differentiate	 between	 a	 surgical	 and	 a	 coagulopathic	 cause.	 The	development	of	bedside	methods	to	assess	coagulation	has	increased	in	interest	during	the	last	decade	since	it	allows	evaluation	of	the	coagulation	and	 can	 address	 type	 of	 coagulopathy	 within	 minutes.		Thromboelastometry	 (ROTEMâ)	 is	 a	 viscoelastic	 analysis	 method	 to	assess	blood	coagulation	in	real	time,	a	technique	first	described	in	1948	(89).	A	small	blood	sample	is	analyzed	regarding	clot	formation,	strength	and	 lysis	 by	 a	 rotating	 sensor	 in	 the	 sample	 tube.	 As	 the	 viscoelastic	strength	 of	 the	 blood	 sample	 increases,	 the	 sensor	 is	 exposed	 to	 an	increasingly	larger	force.	The	result	is	presented	as	a	graphical	reaction	curve		showed	in	Figure	8	(90).	A	clot	formation	dysfunction	leading	to	coagulopathy	 can	 be	 evaluated	 after	 10-15	 minutes	 in	 comparison	 to	standard	 coagulation	 tests	 in	 which	 the	 response	 time	 can	 be	approximately	60	minutes	(91).	To	evaluate	the	contribution	of	fibrinogen	to	 the	 clot,	 the	 analysis	 ROTEMâ	 FIBTEM	 is	 used,	 where	 platelets	 are	inactivated	 by	 cytochalasin	 D.	 In	 cardiac	 surgery,	 thromboelastometry	guided	transfusion	protocols	are	associated	with	reduced	blood	loss	and	
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the	need	for	transfusion	of	blood	products	in	bleeding	patients	(92,	93),	but	 there	 is	 yet	 to	 establish	 whether	 ROTEMâ-guided	 transfusion	protocols	result	in	reduction	in	morbidity	or	mortality.			
Figure	8. Illustration	of	the	thromboelastometry	instrument	and	an	example	of	a	
graph.	CT	(clotting	time)=	the	time	it	takes	for	the	initial	trace	of	coagulation	to	
reach	2	mm,	CFT	(clot	formation	time)=	the	time	it	takes	for	the	clot	amplitude	to	
increase	from	2	to	20	mm,	MCF	(maximum	clot	lysis)=	the	peak	amplitude	of	the	
clot,	ML	(maximum		lysis)=	percent	reduction	in	MCF.		
	
1.4 STUDY OBJECTIVES Excessive	bleeding	and	re-operation	due	to	bleeding	after	cardiac	surgery	remain	a	risk	 factor	 for	 increased	morbidity	and	mortality	 (62-64,	94).	Being	 able	 to	 identify	 patients	 with	 increased	 risk	 of	 bleeding	complications	 is	 appealing	 as	 it	 may	 reveal	 possibilities	 to	 undertake	preventative	 actions.	 There	 has	 been	 an	 increasing	 interest	 in	 the	relationship	between	bleeding	and	plasma	 concentrations	of	 individual	coagulation	factors.	Several	small	studies	found	a	significant	correlation	between	 preoperative	 plasma	 fibrinogen	 concentration	 and	 bleeding	volume	(95-101),	whereas	others	did	not	(102-104).			In	 a	 previous	 study	 from	 our	 group,	 preoperative	 plasma	 level	 of	fibrinogen	 was	 shown	 to	 be	 an	 independent	 risk	 factor,	 not	 only	 for	postoperative	 bleeding	 but	 also	 for	 blood	 transfusion	 in	 patients	
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undergoing	elective	CABG	(100).	The	study	had	obvious	limitations	due	to	the	small	sample	size	and	was	conducted	on	an	isolated	cohort	of	elective	CABG	patients	with	a	low	risk	of	peri-	and	postoperative	bleeding.	In	the	light	of	the	above,	our	objective	in	study	I	was	to	investigate	the	potential	correlation	 between	 preoperative	 plasma	 fibrinogen	 levels	 and	postoperative	bleeding	complications	and	transfusions	in	a	larger	study	population	consisting	of	various	 types	of	cardiac	surgery	procedures.	A	prospective	observational	study	was	designed	where	plasma	fibrinogen	concentration	was	measured	 the	day	before	 surgery	 and	evaluated	 the	correlation	between	 fibrinogen	concentration	and	bleeding	volume	and	transfusion	 of	 RBC’s.	 In	 addition,	 we	 sought	 to	 determine	 other	 risk	factors	for	excessive	bleeding	and	transfusions.		To	further	investigate	the	role	of	fibrinogen	in	postoperative	bleeding,	a	small	 pilot	 study	 (n=20),	 to	 test	 the	 tolerability	 and	 feasibility	 of	prophylactic	administration	of	 fibrinogen	concentrate	 to	CABG	patients	with	low-normal	preoperative	plasma	fibrinogen	concentration,	has	been	performed	 at	 our	 centre.	 In	 that	 study,	 there	 were	 no	 adverse	 events	related	 to	 fibrinogen	 supplementation	 and	 the	 intervention	 seemed	 to	reduce	 the	 postoperative	 bleeding	 volume	 (105).	 The	 study	 was	conducted	on	a	limited	number	of	patients	without	placebo	control,	since	infusion	of	fibrinogen	to	patients	without	ongoing	bleeding	had	not	been	studied	 before.	 In	 study	 II,	 our	 objective	was	 therefore	 to	 confirm	 the	safety	 and	 efficacy	 of	 prophylactic	 fibrinogen	 infusion	 in	 patients	with	fibrinogen	 levels	 in	 the	 lower	normal	 range	undergoing	CABG.	 For	 this	purpose,	a	randomized	placebo-controlled	double-blinded	single	centre	study	 was	 designed,	 where	 the	 primary	 endpoint	 was	 postoperative	bleeding	volume.	The	 use	 of	 fibrinogen	 concentrate	 to	 reduce	 bleeding	 in	 patients	undergoing	cardiac	surgery	has	increased	rapidly	but	little	is	known	about	potential	 side	 effects	 and	 the	 possible	 risk	 of	 thromboembolic	 events	among	 patients	 with	 acquired	 hypofibrinogenemia.	 Data	 based	 on	spontaneous	reports	of	side	effects	when	fibrinogen	concentrate	is	used,	mainly	 in	 patients	 with	 hereditary	 hypofibrinogenemia,	 indicates	 a	beneficial	safety	profile,	with	a	low	incidence	of	adverse	drug	reactions	such	as	 thromboembolic	events	 (106).	More	recent	reports	 in	acquired	hypofibrinogenemia	 cardiovascular	 surgery	 patients	 have	 shown	diverging	 results.	 Two	 studies	 confirm	 the	beneficial	 results(107,	108),	but	 one	 study	 reports	 an	 association	 between	 fibrinogen	 concentrate	administration	and		ischemic	stroke	(109).	Hence,	the	study	objective	in	
study	 III,	 was	 to	 retrospectively	 explore	 the	 safety	 of	 administrating	
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fibrinogen	 concentrate	 to	 cardiac	 surgery	 patients	 in	 a	 large	 study	population.		The	 use	 of	 antifibrinolytics,	 such	 as	 TXA,	 reduces	 both	 peri-	 and	postoperative	blood	loss	and	the	need	for	transfusion	of	blood	products	in	 cardiac	 surgery	 (80,	 81).	 Consequently,	 both	 fibrinogen	 and	 TXA	improve	 hemostasis	 but	 it	 is	 not	 known	 whether	 these	 procoagulants	have	additional	effects	on	hemostasis	when	administered	concomitantly,	compared	to	what	can	be	achieved	individually.	In	study	IV,	an	in	vitro	study	was	designed,	hypothesising	that	the	effect	of	fibrinogen	combined	with	TXA	to	blood	samples	 from	cardiac	 surgery	patients	may	have	an	additive	pro-coagulant	effect	compared	to	fibrinogen	alone.		
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2 STUDY AIMS 	 I. To	investigate	the	relationship	between	the	preoperative	plasma	concentration	of	fibrinogen	and	the	postoperative	bleeding	 volume	 and	 transfusions	 after	 cardiac	 surgery	(study	I).			II. To	 investigate	 if	 preoperative	 administration	 of	fibrinogen	 concentrate	 to	 patients	 with	 low	 normal	fibrinogen	 plasma	 concentration	 reduces	 bleeding	 and	transfusion	requirements	after	elective	CABG	(study	II).		III. To	investigate	if	administration	of	fibrinogen	concentrate	increases	the	risk	of	thromboembolic	complications	and	death	after	cardiac	surgery	(study	III).		IV. To	 investigate	 if	 in	 vitro	 fibrinogen	 supplementation	combined	 with	 tranexamic	 acid	 has	 an	 additive	 pro	coagulant	 effect	 compared	 to	 fibrinogen	 alone	 in	 blood	samples	from	cardiac	surgery	patients	(study	IV).	
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3 PATIENTS AND METHODS 
3.1 PATIENTS The	 four	studies	were	approved	by	 the	Regional	Ethics	Committee	and	were	conducted	in	accordance	with	the	declaration	of	Helsinki.	In	study	I	and	 III,	 the	committee	waived	patient	consent	due	 to	 the	observational	nature	of	the	studies.	In	studies	II	and	IV,	patients	were	included	after	oral	and	 written	 consent.	 Study	 II	 was	 approved	 by	 the	 Swedish	 Medical	Products	Agency	and	registered	at	clinicaltrials.gov	(NCT00968045)	prior	to	 enrollment.	 The	 studies	 were	 all	 performed	 at	 the	 Department	 of	Cardiothoracic	Surgery	at	Sahlgrenska	University	Hospital,	Gothenburg,	Sweden.	Patient	characteristics	in	the	four	studies	are	displayed	in	Table	1.	
Table	1. Patient	characteristics	in	the	four	studies.	Continuous	data	are	shown	as	mean±SD,	
categorical	data	as	number	(%).	
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3.2 METHODS 	
Clinical management CPB	was	performed	in	all	patients.	Anesthesia	was	induced	with	fentanyl,	propolipid	 and	 rocuronium	 and	 maintained	 with	 sevoflurane	 in	 most	cases.	 During	 CPB,	 anesthesia	 was	maintained	with	 propolipid.	 Before	cannulation,	 heparin	 was	 given	 to	 keep	 activated	 clotting	 time	 (ACT)	above	 480	 s.	 After	 CPB,	 protamine	 was	 administered	 to	 reverse	 the	heparin	effect	reducing	ACT	to	less	than	130	s.	All	patients	received	2	g	of	tranexamic	acid	after	induction	of	anesthesia	and	at	the	end	of	surgery.	The	 CPB	 circuit	 consisted	 of	 a	 hollow	 fibre	membrane	 oxygenator	 and	roller	pumps	with	a	standard	non-pulsatile	technique	and	hemodilution.	The	operations	were	performed	 in	normothermia	or	mild	hypothermia	(bladder	temperature	35-36°C).	Cardio	protection	was	achieved	with	cold	blood	cardioplegia.	Weaning	of	CPB	was	performed	after	re-warming	to	a	bladder	 temperature	 of	 36°C.	 Preoperative	 aspirin	 (ASA)	 was	 not	discontinued	 before	 surgery.	 Ticagrelor	 and	 clopidogrel	 were	discontinued	 three	 and	 five	 days	 before	 surgery,	 respectively,	 in	 non-emergent	cases.		The	local	transfusion	protocol	specified	that	RBCs	should	be	transfused	when	 hemoglobin	 (Hb)	 was	 below	 60-70	 g/L	 or	 when	 a	 clinically	significant	 anemia	 occurs.	 Plasma	 should	 be	 transfused	 in	 case	 of	significant	 bleeding	 and	 a	 prolonged	 clotting	 time	 (CT)	 on	thromboelastometry.	Platelets	should	be	transfused	in	case	of	significant	bleeding	and	a	known	or	suspected	platelet	dysfunction		Sustained	effect	of	heparin	was	tested	with	ROTEMâ-HEPTEM	or	ACT	and	reversed	with	protamine.	 Fibrinogen	 was	 administered	 to	 patients	 with	 ongoing	bleeding	and	signs	of	impaired	fibrinogen	function	on	ROTEMâ-FIBTEM	analysis.	Overall,	the	final	decision	regarding	transfusions	and	fibrinogen	administration	was	left	to	the	anestethist	in	charge.	Postoperative	 bleeding	 was	 defined	 as	 the	 total	 amount	 of	 chest	 tube	drainage	 during	 the	 first	 12	 postoperative	 hours	 after	 closure	 of	 the	sternum,	or	until	re-exploration.	A	bleeding	volume	>1000	ml	in	12	hours	was	defined	as	excessive	bleeding.		
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Methods Study I At	total	of	2208	adult	cardiac	operations	were	performed	at	Sahlgrenska	University	Hospital	from	February	2009	to	January	2011.		After	excluding	170	patients	 (6.1%)	due	 to	missing	data,	 a	 total	 of	 1954	patients	were	included	 in	 the	study.	All	elective	and	acute	procedures	were	 included:	CABG,	valve	surgery,	combined	CABG	and	valve	surgery,	GUCH	surgery,	and	arrhythmia	operations,	with	an	exception	of	surgical	procedures	on	the	 ascending	 aorta.	 If	 a	 patient	 underwent	 more	 than	 one	 operation	during	one	hospital	admission	only	the	first	operation	was	included	in	the	analysis.	We	sought	to	investigate	the	correlation	between	preoperative	plasma	 fibrinogen	concentration	and	bleeding	and	transfusion	of	RBC’s	respectively.	The	included	patients	were	also	arbitrarily	divided	into	five	groups	 according	 to	 their	 preoperative	 fibrinogen	 concentration	 (£2.5,	2.6-3.0,	3.1-3.8,	3.9-4.5	and	³4.6	g/L).		Blood	samples	were	collected	the	day	before	surgery	in	elective	cases	or	immediately	 before	 surgery	 in	 acute	 cases.	 Plasma	 fibrinogen	concentration	was	determined	according	to	the	method	by	Clauss	(5)	with	a	reference	value	at	the	time	of	2.0-4.5g/L.	Activated	thromboplastin	time	(APTT),	serum	creatinine,	Hb,	platelet	count	(PLT)	and	prothrombin	time	(PT)	were	measured	preoperatively	and	analyzed	with	standard	clinical	methods.	 The	 total	 amount	 of	 RBC’s,	 plasma	 and	 platelets	 during	 the	hospital	stay	was	recorded.				
Methods study II From	April	2009	to	February	2012,	52	patients	were	included	in	the	study.	Patients	were	eligible	if	they	were	scheduled	for	first	time	elective	CABG	and	 had	 a	 plasma	 fibrinogen	 concentration	 of	 £3.8	 g/L.	 Predefined	exclusion	criteria	were	known	liver-	or	kidney	disease	or	known	bleeding	disorder.	Low	molecular	weight	heparin	(LMWH)	was	discontinued	the	day	before	surgery.	Clopidogrel	and	warfarin	were	withdrawn	at	least	five	days	prior	to	surgery.	Acetyl	salicylic	acid	(ASA)	was	not	discontinued.		
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Figure	9. Flow	chart	for	enrollment,	allocation,	follow	up,	and	analysis.	Patients	were	randomized	to	receive	either	2	g	of	fibrinogen	concentrate	(Haemocomplettanâ;	CSL	Behring,	Marburg,	Germany)	or	placebo,	Figure	9.	 Bleeding	 during	 the	 first	 12	 postoperative	 hours	 was	 compared	between	the	groups.	Secondary	endpoints	were	estimated	intraoperative	bleeding	 volume,	 total	 perioperative	 bleeding	 volume,	 total	 number	 of	transfused	allogenic	 blood	 products,	 proportion	 of	 transfused	patients,	hemoglobin	concentrations	two	and	twenty-four	hours	after	CPB,	plasma	
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fibrinogen	concentration,	PLT,	APTT,	and	PT	before,	during	and	after	CPB.	Preoperative	blood	samples	were	collected	on	the	day	before	surgery.		Subjects	were	 randomized	using	block	 randomization	with	 six	patients	per	group	where	three	patients	received	the	study	drug	and	three	patients	received	placebo.	A	blinded	infusion	of	either	the	study	drug	or	placebo,	prepared	by	the	hospital	pharmacy,	was	administered	after	induction	of	anesthesia	 but	 before	 skin	 incision.	 Patients	 and	 staff	 were	 blinded	regarding	 group	 allocation.	 The	 allocation	 list	 was	 not	 broken	 until	completion	of	the	study	and	after	data	analysis.		Plasma	fibrinogen	concentration	was	measured	according	to	the	method	of	Clauss	with	a	reference	interval	of	2.0-4.5	g/L.	Hb,	PLT	,PT,	APTT	and	serum	 creatinine	 level	were	measured	with	 standard	 clinical	methods.	Thromboelastometry	was	not	used	routinely,	but	was	utilized	in	case	of	bleeding.	 Fibrinogen	 was	 administered	 outside	 the	 study	 protocol	 to	patients	with	ongoing	bleeding	and	a	ROTEMâ-FIBTEM	analysis	result	of	less	than	10	mm.		
Methods Study III All	patients	who	underwent	first-time	cardiac	surgery	at	our	department	between	2009	and	2014	were	included	in	a	retrospective	observational	study.	All	 types	of	cardiac	surgery	were	 included:	CABG,	valve	surgery,	combined	 CABG-	 and	 valve	 surgery,	 GUCH	 surgery	 and	 arrhythmia	operations.	Patients	who	underwent	surgery	on	the	ascending	aorta,	and	re-sternotomies	were	excluded.	In	total,	6442	patients	were	assessed	for	inclusion,	and	5408	were	included,	Figure	10.		
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Figure	10. Patients	assessed	for	inclusion	in	study	III.	Patient	characteristics,	type	of	surgery,	pre-	and	postoperative	laboratory	testing,	 bleeding	 volume,	 number	 of	 transfusions	 and	 fibrinogen	administration	were	retrospectively	collected	 from	patient	records	and	the	Swedish	Heart	Surgery	Registry	(110).	The	National	Patient	Registry	(NPR)	and	the	Cause	of	Death	Registry	supplied	data	on	thromboembolic	complications	and	death	(111,	112).	The	merging	of	data	was	possible	by	using	the	social	security	number	given	to	each	Swedish	citizen.		
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The	incidence	of	a	composite	of	thromboembolic	events	and	mortality	at	one	year	 after	 surgery	were	 compared	between	patients	who	 received	perioperative	fibrinogen	concentrate	and	patients	who	did	not.	Secondary	endpoints	were	the	incidence	of	the	composite	endpoint	at	30	days	and	mortality	at	30	days	and	1	year	respectively.		
Table	2. ICD-codes	in	the	composite	endpoint.	
Methods Study IV Fifteen	 patients	 scheduled	 for	 first-time	 elective	 CABG	 between	November	2017	to	January	2018	and	a	plasma	fibrinogen	concentration	within	the	normal	range	(1.8-3.8	g/L)	were	included.	At	the	time	of	this	study,	 the	 hospital	 implemented	 a	 new	 reference	 interval	 for	 plasma	fibrinogen	concentration	due	to	both	a	new	instrument	and	a	new	reagent.	All	included	patients	were	preoperatively	treated	with	ASA	which	was	not	discontinued	 before	 surgery.	 Exclusion	 criteria	 were	 known	 bleeding	disorder,	 renal	disease,	and	on-going	 treatment	with	platelet	 inhibiting	agents	and	anti-coagulant	agents	that	was	not	discontinued	according	to	institutional	practice.		In	 accordance	 with	 our	 institutional	 protocol,	 two	 grams	 of	 TXA	 was	administered	after	 induction	of	anesthesia,	but	before	surgical	 incision,	and	at	the	end	of	surgery.	Blood	samples	for	clot	formation	analyses	were	
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collected	 before	 and	 five	 minutes	 after	 both	 TXA	 doses.	 Samples	 for	platelet	count,	hemoglobin	and	plasma	fibrinogen	concentration	analyses	were	 collected	 the	 day	 before	 surgery	 and	 immediately	 prior	 to	 the	second	dose	of	TXA.		For	each	subject,	two	portions	at	each	sample	occasion	were	prepared	for	ROTEMâ-FIBTEM	analysis,	giving	a	 total	 of	 eight	 samples,	 presented	 in	Figure	11	and	12.	All	samples	collected	before	surgery	were	diluted	with	Ringer’s	 Acetate	 to	 achieve	 a	 hemodilution	 of	 21%	 in	 order	 to	 mimic	hemodilution	 during	 CPB.	 After	 dilution,	 fibrinogen	 concentrate	 was	added	in	a	dose	corresponding	to	3	g	fibrinogen	given	to	a	70	kg	patient.			
Figure	11. Preoperative	samples	prepared	for	thromboelastometry.	Baseline	
sample	contains	blood	diluted	with	Ringer’s	Acetate.	WB=whole	blood(red);	
RA=Ringers	Acetate	(blue);	TXA=tranexamic	acid	(yellow);	FIB=fibrinogen	(green)	
	
Figure	12. Postoperative	samples	prepared	for	thromboelastometry.	WB=whole	
blood(red);	TXA=tranexamic	acid(yellow);	FIB=fibrinogen(green)	The	 clot	 formation	 process	 was	 assessed	 with	 thromboelastometry	(ROTEMâ).	 ROTEMâ-FIBTEM	 in	 which	 clot	 formation	 is	 activated	 by	tissue	 factor	 was	 used.	 Changes	 in	 clotting	 time	 CT),	 maximum	 clot	firmness	(MCF)	and	clot	lysis	(ML)	were	compared	between	the	samples.		
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3.3 STATISTICAL ANALYSES  For	all	studies,	data	are	presented	as	mean	with	standard	deviation	(SD),	median	with	 interquartile	 range	 (IQR)	 or	 proportions	with	 percentage	(%)	 as	 described.	 Any	 p-value	 <0.05	 was	 considered	 statistically	significant.		
Study	I	Categorical	 variables	were	 compared	 between	 the	 groups	with	c2-test	and	continuous	variables	with	one	way	analysis	of	variance	(ANOVA).	The	importance	 of	 fibrinogen	 concentration	 for	postoperative	 bleeding	 and	transfusion	were	analyzed	by	handling	the	explanatory	and	the	outcome	variable	 as	 continuous	 variables	 by	 univariate	 testing	 and	 multiple	models	 with	 fibrinogen	 as	 a	 continuous	 variable	 and	 bleeding	 as	 a	dichotomous	variable	(<1000	ml/12	h	and	>1000	ml/12	h).	Bleeding	and	transfusions	 of	 RBCs	 were	 also	 compared	 between	 the	 subgroups	according	to	preoperative	plasma	concentration	of	fibrinogen.	To	 explore	 risk	 factors	 for	 bleeding	 >1000	 ml	 in	 12	 hours	 and	transfusions,	 univariate	 and	 multivariable	 logistic	 regression	 was	performed	 and	 presented	 as	 odds	 ratios	 (OR)	 with	 95%	 confidence	intervals	 (CI).	 All	 factors	 univariately	 associated	 with	 bleeding	 or	transfusion	were	used	in	the	multivariable	models.	
Study II	Normality	 of	 distribution	 was	 tested	 with	 Shapiro-Wilk	 test.	 Group	comparisons	in	normally	distributed	continuous	data	were	made	with	the	Student’s	 t-test	 and	 in	 non-normally	 distributed	 data	 with	 the	 Mann-Whitney	U-test.	 The	c2-test	was	used	 to	 compare	 categorical	 data.	 For	group	 comparisons	 of	 variables	 analyzed	 at	 more	 than	 one	 occasion,	ANOVA	for	repeated	measurements	was	used,	followed	by	the	Students	t-test	if	ANOVA	indicated	a	difference.	Changes	from	baseline	within	a	group	were	analyzed	with	a	paired	t-test.		A	power	calculation,	based	on	 the	previously	described	pilot	study	was	made	 (105).	 To	 show	 a	 30%	 reduction	 in	 bleeding	 volume	 in	 the	treatment	group,	25	patients	were	needed	in	each	group	with	80%	power	and	a	significance	level	of	0.05.			
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Study III Categorical	variables	were	compared	between	the	groups	with	the	c2-test	or	Fisher’s	 test	 if	 small	 numbers.	 Continuous	variables	were	 compared	between	the	groups	with	the	t-test	or	the	Mann-Whitney	test	depending	on	 variable	 distribution.	 	 To	 assess	 the	 importance	 of	 fibrinogen	concentrate	administration	for	the	composite	event	and	mortality	at	30	days	 postoperatively,	 univariate	 and	 multivariable	 logistic	 regression	analyses	was	used.	To	 assess	 the	 importance	of	 fibrinogen	 concentrate	administration	for	survival	time	and	time	to	the	composite	event	up	to	one	year,	univariate	and	multivariable	Cox	regression	analyses	were	used.	The	variables	that	were	statistically	significant	in	the	univariate	model	were	included	 in	 the	multivariable	 logistic	 regression	model	 and	 in	 the	 Cox	regression	model.	Two	propensity	score-based	sensitivity	analyses	were	performed,	 based	 on	 the	 probability	 of	 administration	 of	 fibrinogen	concentrate.			
Study IV To	be	able	to	detect	a	20%	(2	mm)	change	in	FIBTEM-MCF	with	a	standard	deviation	 of	 2.5	 mm,	 80%	 power	 and	 a	 significance	 level	 of	 0.05,	 12	patients	were	needed.	To	 achieve	marginal,	 15	patients	were	 included.	The	 non-parametric	Wilcoxon	 signed	 paired	 test	was	 used	 to	 compare	results	from	baseline	and	after	addition	of	TXA,	fibrinogen	and	TXA	plus	fibrinogen,	respectively.		
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4 RESULTS 
4.1 PREOPERATIVE PLASMA 
CONCENTRATION OF FIBRINOGEN, 
BLEEDING AND TRANSFUSIONS (I) The	mean	plasma	fibrinogen	concentration	in	the	cohort	was	3.8±1.0	g/L.	Eight	patients	(0.41%)	had	a	fibrinogen	concentration	below	the	normal	reference	 limit	 (2.0	 g/L)	 and	 370	 patients	 (17%)	 had	 a	 concentration	above	 the	 normal	 reference	 limit	 (4.5	 g/L).	 Table	 3	 illustrates	 patient	characteristics	in	relation	to	preoperative	fibrinogen	concentration.		
Table	3. Patient	characteristics	in	relation	to	preoperative	fibrinogen	concentration.	
Continuous	data	are	shown	as	mean±SD,	categorical	data	as	number	(%).		
Bleeding The	mean	bleeding	volume	was	563±374	ml/12	hours	 and	96	patients	(4.9%)	 underwent	 re-exploration	 due	 to	 excessive	 bleeding	 or	tamponade.	 Ten	 percent	 of	 the	 patients	 had	 a	 postoperative	 bleeding	volume	 of	 more	 than	 1000	 ml/12	 hours.	 There	 was	 a	 weak	 inverse	correlation	 between	 preoperative	 fibrinogen	 concentration	 and	postoperative	bleeding	volume	(r=-0.17,	p<0.001).	Patient	characteristics	and	univariate	risk	factors	for	bleeding	>1000	ml/12	hours	are	presented	
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in	 Table	 4.	 Independent	 risk	 factors	 for	 excessive	 bleeding	 were	 low	fibrinogen	concentration,	low	BMI,	longer	CPB	time,	clopidogrel	intake	<5	days	before	surgery,	low	preoperative	platelet	count	and	acute	operation.		
Table	4. Univariate	risk	factors	for	bleeding	£1000	ml		or	>1000	ml/Hours	(n=	1954).	
Continuous	data	are	shown	as	mean±SD,	categorical	data	as	number	(%).	When	dividing	patients	 into	 subgroups	according	 to	 their	preoperative	fibrinogen	 concentration,	 the	 patients	with	 the	 lower	 fibrinogen	 levels	had	 both	 a	 higher	 postoperative	 mean	 bleeding	 volume	 and	 a	 higher	percentage	 of	 excessive	 bleeding.	 Re-operation	 for	 bleeding	was	more	common	 in	 patients	with	 the	 highest	 and	 the	 lowest	 fibrinogen	 levels,	illustrated	in	Figure	13.		In	multivariable	analysis,	patients	with	the	lowest	fibrinogen	concentration	still	had	a	significant	increased	risk	of	bleeding	>1000	 ml/12	 hours	 compared	 to	 patients	 with	 the	 highest	 levels,	presented	in	Table	5.						
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Figure	13. (A)Unadjusted	mean	postoperative	blood	loss,	(B)	blood	loss	exceeding	
1000	ml/12	h	(C)	re-exploration	rate	(D)	proportions	of	patients	receiving	RBC	in	
patients	with	different	fibrinogen	concentrations.	Error	bars	indicate	SD.		
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Table	5. Unadjusted	and	adjusted	Odds	Ratios	(OR)	for	bleeding	over	1000	ml/12	h	in	
subgroups	with	different	fibrinogen	concentrations.	
 
Transfusions	There	 was	 a	 weak	 correlation	 between	 preoperative	 fibrinogen	concentration	and	the	number	of	RBC	transfusions	(r=0.14,	p=	<0.001).	Patient	characteristics	and	univariate	risk	factors	for	RBC	transfusion	are	presented	in	Table	6.	In	the	multivariable	analysis,	low	fibrinogen	levels	were	not	associated	with	an	increased	risk	of	RBC	transfusion	(OR	1.10;	95%	CI	0.89-1.28	per	g/L,	p=0.49).	Independent	factors	associated	with	RBC	transfusion	were	acute	operation,	impaired	renal	function,	long	CPB-time,	 clopidogrel	 intake	 <5	 days	 before	 surgery	 and	 low	 preoperative	hemoglobin	 concentration.	 Within	 the	 fibrinogen	 concentration	subgroups,	there	was	no	significant	difference	in	risk	of	transfusion	of	RBC	and	fibrinogen	concentration	in	the	multivariable	analysis.							
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Table	6. Univariate	risk	factors	for	RBC	transfusion	(n=1954).	Continuous	data	are	shown	
as	mean±SD,	categorical	data	as	number	(%).		
4.2 PROPHYLACTIC TREATMENT WITH 
FIBRINOGEN CONCENTRATE (II) Mean	preoperative	plasma	 fibrinogen	concentration	was	3.0±0.4	g/L	in	the	treatment	group	and	3.0±0.4	in	the	placebo	group	(p=0.81).	Infusion	of	fibrinogen	concentrate	increased	plasma	fibrinogen	concentration	by	0.2±0.4	 g/L	 and	 infusion	 of	 placebo	 decreased	 the	 concentration	 by	0.2±0.4	g/L	(p=	0.004	between	the	groups).	There	 was	 no	 significant	 difference	 between	 the	 groups	 in	 median	postoperative	 bleeding	 within	 12	 hours,	 nor	 in	 any	 other	 bleeding	estimates	 or	 transfusions.	 Five	 patients	 in	 each	 group	 bled	more	 than	1000	 ml.	 Variables	 of	 postoperative	 bleeding	 and	 transfusions	 are	displayed	in	Figure	14	and	Table	7.	Changes	of	fibrinogen	concentration	over	time	are	presented	in	Figure	15.				
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Figure	14. Postoperative	bleeding	volume	in	individual	subjects.	There	was	no	
significant	difference	in	median	bleeding	volume	between	the	groups	(p=0.29).		
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Table	7. Bleeding	and	transfusions.	Continuous	data	are	shown	as	mean±SD	and	median	
(25th	and	75th	percentiles),		categorical	data	as	number	(%).	
Figure	15. Changes	in	fibrinogen	concentration	(g/L)		over	time.		Aortic	 clamp	 time	 and	 CPB	 time	 were	 significantly	 longer	 and	preoperative	Hb	and	Hct	were	significantly	higher	in	the	treatment	group	than	in	the	placebo	group.	There	were	no	clinically	detectable	side	effects	
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of	 fibrinogen	 infusion.	 One	 patient	 in	 the	 placebo	 group	 had	 signs	 of	postoperative	ischemia	and	heart	failure	where	angiography	revealed	an	occluded	 vein	 graft.	 Fibrinogen	 concentrate	 was	 administered	postoperatively	 outside	 the	 study	 protocol	 to	 three	 patients	 in	 the	treatment	group	and	to	seven	in	the	placebo	group.			
4.3 FIBRINOGEN ADMINISTRATION AND RISK 
OF THROMBOEMBOLIC COMPLICATIONS 
(III) 	Patient	 characteristics,	 divided	 into	 patients	 who	 received	 fibrinogen	concentrate	and	patients	who	did	not,	are	displayed	in	Table	8.			
One year outcome After	one	year,	nearly	10%	of	the	included	patients	had	had	at	least	one	event	 included	 in	 the	 composite	 endpoint	 and	 the	 mortality	 rate	 was	4.8%,	Table	9.	The	patients	who	did	receive	 fibrinogen	concentrate	did	not	have	a	higher	risk	for	thromboembolic	complications	or	death	after	adjustment	for	covariates,	Table	10,	Figure	16.		
Katarina	Waldén	
35	
	
Table	8. Patient	characteristics,	divided	into	patients	who	received	fibrinogen	concentrate	
and	those	who	did	not.	Continuous	data	are	shown	as	mean±SD	and	median	(25th	and	75th	
percentiles),		categorical	data	as	number	(%).		
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Table	9. Unadjusted	outcome	variables	at	one	year	after	surgery	in	patients	who	did	and	
did	not	receive	fibrinogen	concentrate	perioperatively.		
Table	10. Association	between	fibrinogen	concentrate	administration	and	composite	
endpoint	and		mortality	during	the	first	year	after	surgery.	Hazard	ratios	(HR)	based	on	Cox	
regression	models	are	presented.a	composite	endpoint	b	unadjusted	HR		c	adjusted	HR	
adjusted	for	age,	sex,	BMI,	diabetes,	preoperative	antiplatelet	therapy,	plasma	fibrinogen	
concentration,	Hb,	PLT	count,	preoperative	serum-creatinine,	PT,	history	of	ischemic	stroke,	
EuroSCORE	I,	CPB	time,	surgical	procedure	and	total	perioperative	transfusions	d	
unadjusted	HR,	HR	adjusted	for	see	c.	
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Figure	16. Adjusted	incidence	of	the	composite	endpoint	during	the	first	
postoperative	year.		
	
30 days outcome At	 30	 days,	 3.5	 %	 of	 the	 patients	 had	 had	 an	 event	 included	 in	 the	composite	endpoint	and	the	mortality	rate	was	2.3%.	The	patients	who	did	receive	fibrinogen	concentrate	did	not	have	a	significantly	higher	risk	of	 thromboembolic	 complications	 or	 death	 after	 adjustment	 for	covariates,	Table	11.		 	
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Table	11. Associations	between	fibrinogen	concentrate	administration	and	composite	
endpoint	and	mortality	30	days	after	surgery.	Odds	ratios	(OR)	based	on	univariate	and	
multivariable	logistic	regression	models	are	presented.	a	Composite	endpoint	b	unadjusted	
OR	c OR	adjusted	for	age,	sex,	preoperative	antiplatelet	therapy,	preoperative	plasma	
fibrinogen	concentration,	platelet	count,	preoperative	serum	creatinine,	prothrombin	time,	
history	of	ischemic	stroke,	CPB	time,	diabetes,	total	perioperative	transfusions,	EuroSCORE	
1,	surgical	procedure	dUnadjusted	OR	for	mortality	e	OR	for	mortality	adjusted	for	age,	sex,	
preoperative	prothrombin	time,	preoperative	fibrinogen	concentration,	hemoglobin	
concentration,	preoperative	platelet	count,	antiplatelet	therapy,	preoperative	serum	
creatinine,	CPB	time,	EuroSCORE	1,	surgical	procedure,	total	perioperative	transfusions.		
4.4 FIBRINOGEN SUPPLEMENTATION AND 
TRANEXAMIC ACID ADMINISTRATION (IV) Median	preoperative	plasma	 fibrinogen	concentration	was	3.3	(2.9-3.6)	g/L.	 The	 hemoglobin	 concentration,	 platelet	 count,	 hematocrit	 and	fibrinogen	concentration	were	significantly	reduced	at	the	end	of	surgery.	None	of	the	samples	showed	signs	of	fibrinolysis	after	30	minutes.	Fibrinogen	 supplementation,	 with	 or	 without	 the	 presence	 of	 TXA	shortened	 CT	 and	 increased	 MCF,	 both	 preoperatively	 and	postoperatively.	 Before	 surgery,	 fibrinogen	 supplementation	 shortened	CT	 somewhat	 more	 after	 TXA	 administration	 while	 there	 was	 no	difference	in	effect	in	relation	to	TXA	administration	after	surgery,	Figure	17.	The	enhancing	effect	of	fibrinogen	supplementation	on	MCF	did	not	differ	significantly	before	and	after	TXA	administration	neither	before	nor	after	surgery,	Figure	18.			
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Figure	17. Changes	from	baseline	in	CT		from	after	addition	of	TXA,	fibrinogen	or	
both	in	%.	Baseline	CT	was	72	(70-78)	and	107	(81-118)	seconds	in	the	pre-	and	
postoperative	samples,	respectively.	Median	and	25th	and	75th	percentiles.•	p<0.05,	
••	p<0.01	•••	p	<0.001	vs	baseline.		
Figure	18. Changes	from	baseline	in	MCF	after	addition	of	TXA,	fibrinogen	or	both	
in	%.	Baseline	MCF	was	14	(9-15)	and	14	(13-15)	mm	in	the	pre-	and	
postoperative	samples,	respectively.	Median	and	25th	and	75th	percentiles.	•p<0.05,	
••	p<0.01	•••	p	<0.001	vs	baseline.	
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5 DISCUSSION 
5.1 FIBRINOGEN CONCENTRATION, 
BLEEDING AND TRANSFUSIONS (I) Fibrinogen	and	its	role	in	hemostasis	and	bleeding	has	been	thoroughly	investigated	 in	 the	 last	 decade.	 For	 many	 years,	 a	 plasma	 fibrinogen	concentration	of	at	least	1.0	g/L	was	considered	to	be	enough	to	ensure	a	stable	clot	 formation	not	 limited	by	 fibrinogen	concentration	 in	case	of	bleeding	 (21,	 113).	 In	 study	 I,	 the	main	 finding	 was	 that	 preoperative	plasma	concentration	of	less	than	2.5	g/L	was	independently	associated	with	 increased	 postoperative	 bleeding.	 Fibrinogen	 levels	 below	 the	normal	reference	level	are	rare	in	patients	without	ongoing	bleeding	and	the	low	prevalence	of	low	fibrinogen	levels	was	confirmed	in	our	cohort.	Only	0.4	%	of	the	patients	had	a	fibrinogen	concentration	below	2.0	g/L.	The	 question	 is	 what	 endogenous	 fibrinogen	 concentration	 that	 is	sufficient	for	maintaining	a	stable	coagulation	process	when	the	system	is	challenged	during	major	 surgical	 procedures,	 like	 cardiac	 surgery	with	CPB	 and/or	 ongoing	 bleeding.	 During	 CPB,	 there	 is	 a	 decrease	 in	fibrinogen	 concentration	 by	 approximately	 30%,	 mainly	 caused	 by	hemodilution	 during	 CPB	 (103,	 114).	 A	 preoperative	 level	 of	 2.5	 g/L,	which	 in	 our	 study	 occurred	 in	 about	 5	%	 of	 the	 patients,	 is	 thereby	reduced	to	approximately	1.75	g/L,	which	is	under	the	normal	reference	range,	and	on	the	verge	of	the	level	where	recent	guidelines	recommend	fibrinogen	 substitution	 in	 case	 of	 bleeding	 (115).	 Hemodilution	 also	reduces	 the	concentration	of	other	coagulation	 factors	 (103).	However,	supplementation	with	 only	 fibrinogen	 concentrate	 normalized	MCF,	 at	least	 in	 vitro	 (114).	 This	 indicates	 that	 fibrinogen	 might	 be	 a	 more	important	limiting	factor	for	whole	blood	clotting	than	other	coagulation	factors	and	platelets	in	the	case	of	hemodilution.		In	 this	 study,	 we	 found	 a	 weak	 (r=-0.17),	 but	 statistically	 significant	correlation	 between	 preoperative	 concentration	 of	 fibrinogen	 and	postoperative	bleeding	volume,	but	far	too	weak	to	establish	any	clinical	conclusions.	This	is	in	contrast	to	several	other	studies	(98,	100,	116)	and	a	meta-analysis	by	Gielen	et	al	(117)	which	showed	stronger	correlations.	Differences	in	study	populations	may	explain	the	variances.		The	 relationship	 between	 low	 preoperative	 levels	 of	 fibrinogen	concentration	became	more	apparent	when	we	instead	of	overall	bleeding	volume	 focused	 on	 the	 risk	 of	 excessive	 bleeding	 (defined	 as	 bleeding	
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>1000	ml/12	h).	The	reduction	of	fibrinogen	by	1g/L	(one	unit),	increased	the	 risk	 of	 excessive	 bleeding	 by	 25%,	 even	 after	 correction	 for	 other	factors	that	have	an	impact	on	postoperative	bleeding.		Moreover,	patients	in	the	group	with	the	lowest	levels	of	fibrinogen,	had	an	almost	threefold	risk	 of	 excessive	 bleeding	 compared	 to	 the	 patients	 with	 the	 highest	fibrinogen	 levels.	 This	 study	 thus	 supports	 the	 theory	 that	 low	plasma	fibrinogen	concentration	is	associated	with	excessive	bleeding.	But,	even	if	fibrinogen	turned	out	to	be	an	independent	predictor	of	postoperative	bleeding,	the	relative	importance	of	fibrinogen	level	is	difficult	to	evaluate.	The	results	from	the	multivariable	analyses	implicate	that	other	factors	such	 as	 acute	 operation,	 ongoing	 or	 recently	 stopped	 dual	 antiplatelet	therapy	and	duration	of	the	operation	are	more	important.		Transfusion	of	blood	products	can	be	 lifesaving	but	 it	 is	also	related	 to	complications	 such	 as	 acute	 lung	 injury,	 hemolytic	 reactions,	 allergic	reactions,	 possible	 transfer	 of	 unknown	 pathogens	 and	immunomodulation.	Over	the	years,	it	has	been	suggested	that	allogenic	blood	transfusions	lead	to	increased	morbidity	and	mortality	in	patients	undergoing	cardiac	surgery.	It	has	in	fact	been	suggested	that	as	little	as	one	 or	 two	 units	 of	 RBCs	 do	 increase	 the	 mortality	 risk	 	 and	 severe	complications	 such	 as	 infections	 and	 ischemic	 events	 (118,	 119).	However,	 the	 evidence	 comes	 from	 retrospective	observational	 studies	where	it	is	difficult	to	adjust	for	the	worse	condition	of	patients	receiving	transfusions.	 More	 recent	 prospective	 randomized	 studies	 comparing	liberal	 and	 restrictive	 transfusion	 protocols	 have	 shown	 somewhat	diverging	 results.	 In	 the	TITRE-2	 study	 (79)	 the	 restrictive	 transfusion	protocol	 was	 associated	with	 an	 increased	mortality	 risk,	 while	 in	 the	TRICS	study	(78)	no	such	association	was	found.	Contrarily	in	the	latter	study,	 older	 patients	 seem	 to	 benefit	 from	 a	 restrictive	 transfusion	protocol,	regarding	mortality	risk.		In	 study	 I,	 univariate	 analysis	 indicated	 that	 a	 high	 preoperative	fibrinogen	 concentration	 increased	 the	 risk	 of	 blood	 transfusion.	However,	these	patients	were	older,	had	lower	preoperative	hemoglobin	levels,	were	more	 often	 female	 and	more	 likely	 to	 be	 undergoing	 non-elective	 surgery.	 All	 of	 these	 are	 already	 known	 risk	 factors	 for	transfusions.	Hence,	after	adjustment,	there	was	no	longer	an	association	between	preoperative	 fibrinogen	 levels	and	 transfusions.	Other	 studies	have	however	found	associations	between	low	fibrinogen	concentration	and	 transfusion	 requirements	 (100,	 101,	 120)	 while	 some	 studies,	including	study	 I,	have,	not	 found	any	associations	after	adjustment	for	confounding	factors	(102,	121).	
The	use	of	fibrinogen	in	cardiac	surgery	patients	
42	
Interestingly,	postoperative	bleeding	volume	did	not	appear	to	be	a	risk	factor	for	transfusion.	This	emphasizes	that	the	decision	to	transfuse	is	far	more	complex	 than	simply	substituting	a	loss	of	blood.	 It	 is	therefore	a	challenge	 to	 draw	 conclusions	 about	 bleeding	 and	 transfusions,	 since	several	 of	 the	 variables	 that	 influence	 transfusion,	 are	 also	 related	 to	postoperative	bleeding	volume	and	low	fibrinogen	levels.		
5.2 TREATMENT WITH FIBRINOGEN 
CONCENTRATE (II) Two	 previous	 small	 studies	 from	 our	 group	 have	 shown	 an	 inverse	relationship	between	the	preoperative	fibrinogen	concentration	and	the	postoperative	bleeding	volume	after	cardiac	surgery	(98,	100).	In	2008,		a	small	randomized	pilot	study	was	conducted,	where	patients	undergoing	CABG	 surgery	 were	 randomized	 to	 receive	 either	 2	 g	 of	 fibrinogen	concentrate	or	nothing	before	 the	surgery	(105).	The	study	 focused	on	safety	 aspects	 including	 graft	 patency.	 The	 results	 were	 in	 favor	 of	prophylactic	 fibrinogen	 supplementation	 since	 there	 was	 a	 significant	decrease	in	postoperative	bleeding	among	the	patients	who	had	received	fibrinogen	 concentrate.	 No	 significant	 increase	 in	 adverse	 events	 was	detected.	Based	on	these	findings,	we	performed	a	larger	study	in	study	II	to	further	investigate	the	suggested	benefit	of	prophylactic	treatment	with	fibrinogen	 concentrate	 to	 reduce	bleeding	and	blood	 transfusions	after	CABG	surgery.	However,	the	results	of	the	pilot	study	regarding	efficacy	were	 not	 reproduced	 in	 the	 present	 study.	 There	 was	 no	 significant	difference	between	the	groups	regarding	postoperative	bleeding	volume,	nor	hemoglobin	 levels,	while	no	 safety	 concerns	occurred.	The	present	study	 had	 an	 improved	 study	 design	 (randomized,	 blinded,	 placebo	controlled)	and	was	carried	out	on	a	larger	cohort	of	patients	and	is	thus	more	valid	than	the	initial	pilot	study.	Hence,	the	study	gives	no	support	for	the	concept	of	prophylactic	administration	of	fibrinogen	concentrate	to	 low-risk	 CABG	 patients	 with	 low-normal	 preoperative	 fibrinogen	levels.	This	does	not	exclude	that	there	may	be	patients	who	would	benefit	from	 prophylactic	 fibrinogen	 administration,	 e.g.	 those	 with	 lower	fibrinogen	concentrations	and/or	more	complex	procedures.	 In	study	 I,	18%	of	the	patients	with	a	fibrinogen	concentration	below	2.5	g/L	had	an	excessive	postoperative	bleeding,	when	compared	to	7%	of	the	patients	with	a	fibrinogen	concentration	³4.6	g/L.	In	a	group	consisting	of	CABG	patients	only,	the	difference	was	even	larger	15	%	vs	3.5%,	i.e.	a	fourfold	increase	 in	 bleeding	 among	 patients	 with	 low	 fibrinogen	 levels.	 These	large	 differences	 indicate	 that	 increasing	 fibrinogen	 levels	 might	 be	
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beneficial	 in	 patients	 with	 really	 low	 preoperative	 fibrinogen	concentrations,	 given	 the	 increased	 mortality	 risk	 in	 patients	 with	excessive	bleeding	(62,	64).		Guidelines	from	the	European	Society	of	Anesthesiology	2013	comprised	a	 recommendation	 to	 consider	 a	prophylactic	 infusion	 of	 fibrinogen	 in	patients	with	a	level	<3.8	g/L	undergoing	CABG,	based	on	our	pilot	study	(122).	 After	 study	 II,	 this	 recommendation	 is	 now	 withdrawn.		Considering	the	patient	cohort	with	a	level	under	2.5	g/L,	there	might	be	a	rationale	for	prophylactic	treatment,	where	less	than	5%	of	the	patients	would	be	treated	(123).		During	 the	 past	 years,	 a	 few	 prospective	 randomized	 studies	 has	 been	carried	 out	 with	 the	 notion	 to	 use	 fibrinogen	 concentrate	 to	 reduce	bleeding	 complications	 and	 transfusion	 requirements	 in	 cardiovascular	surgery	 (124-126).	Most	 of	 the	 studies	have	been	 focusing	on	 complex	cardiac	 surgery,	with	 a	 higher	 risk	 of	 bleeding	 than	 the	 elective	 CABG	patients	included	in	our	pilot	study	and	in	study	II.	A	significant	reduction	of	both	postoperative	bleeding	volume	and	transfusion	of	allogenic	blood	products	 was	 observed	 in	 a	 study	 carried	 out	 on	 higher	 risk	 cardiac	surgery	patients,	where	fibrinogen	concentrate	administration	was	given	after	 weaning	 of	 CPB	 (125).	 The	 median	 dose	 was	 4	 g	 and	 based	 on	calculated	 target	 FIBTEM.	 Another	 study,	 with	 primary	 endpoint	 to	reduce	intraoperative	blood	loss	in	complex	cardiac	surgery	(mean	dose	3	g/L,	target	>2.5g/L)	after	weaning	of	CPB	and	before	sternum	closure	did	not	result	in	reduced	bleeding	volume	(126).	Hence,	the	question	if	the	use	of	fibrinogen	concentrate	might	reduce	bleeding	induced	morbidity	and	mortality	is	still	to	be	answered.	Currently,	the	recommendation	to	use	fibrinogen	concentrate	is	restricted	to	patients	with	ongoing	bleeding	and	probable	or	confirmed	hypofibrinogenemia	(115,	127,	128).		
5.3 FIBRINOGEN ADMINISTRATION AND RISK 
OF COMPLICATIONS (III) In	 study	 III,	 we	 compared	 patients	 who	 had	 received	 fibrinogen	concentrate	 due	 to	 bleeding	 in	 the	 perioperative	 period,	 with	 patients	who	had	not	received	fibrinogen	concentrate.	The	aim	of	the	study	was	to	investigate	if	administration	of	fibrinogen	concentrate	is	associated	with	increased	risk	of	thromboembolic	complications	and	/or	death	analyzed	
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30	days	and	one	year	after	surgery.	A	composite	endpoint	was	used	and	the	 results	 showed	 no	 increased	 risk	 of	 neither	 thromboembolic	complications	nor	death	within	this	follow-up	time.	Besides	 its	 essential	 effects	 on	 hemostasis,	 elevated	 fibrinogen	 levels	indicate	 inflammation	 and	 is	 also	 a	 strong	 marker	 for	 cardiovascular	disease	and	mortality.	It	is	well	known	that	increased	local	aggregation	of	platelets	in	atherosclerotic	lesions,	in	which	fibrinogen	has	a	major	role,	is	 a	process	 that	 is	 the	beginning	of	 a	 vaso-occlusive	 thrombotic	 event	such	as	myocardial	infarction	and	ischemic	stroke.	Furthermore,	elevated	fibrinogen	levels	are	frequently	seen	in	patients	with	transient	ischemic	attacks	and	ischemic	stroke	(15).		The	 acute	 effects	 on	 hemostasis	 and	 the	 correlation	 between	 elevated	plasma	concentrations	of	fibrinogen	and	cardiovascular	disease	raise	the	question	whether	 it	 is	 safe	 to	 administer	 fibrinogen	 as	 a	 procoagulant	treatment	in	case	of	bleeding	complications.	Further,	the	potential	long-term	 side	 effects	 such	 as	 thromboembolic	 complications	 when	administrating	fibrinogen	concentrate	are	not	completely	known.		Studies	focusing	on	the	safety	of	fibrinogen	concentrate	administration	to	reduce	perioperative	bleeding	have	shown	diverging	results.	Fassl	et	al	compared	two	PS-matched	groups	from	an	original	cohort	of	991cardiac	surgery	patients	in	which	20%	received	fibrinogen	concentrate	(107).	The	study	 did	 not	 detect	 any	 increased	 risk	 of	 thromboembolic	 events	 or	mortality	within	30	days	or	at	one	year.	Maeda	et	al	studied	a	cohort	of	1047	 patients	 undergoing	 thoracic	 aortic	 surgery	 in	which	24%	 of	 the	patients	received	fibrinogen	concentrate	or	cryoprecipitate	(108).	In	a	PS-based	 analysis,	 there	 was	 no	 significant	 difference	 in	 thromboembolic	events	or	mortality	at	30	days.	In	contrast	to	these	two	studies,	Jakobsen	et	 al	 found	 that	 perioperative	 administration	 of	 fibrinogen	 was	 an	independent	 risk	 factor	 for	 postoperative	 stroke	 and	 renal	 failure	 in	 a	cohort	 of	 1876	 patients	 of	 whom	 10%	 had	 received	 fibrinogen	concentrate	(109).		The	 present	 study,	 which	 is	 markedly	 larger	 than	 the	 previous	 ones,	confirms	 the	 results	 from	 Fassl’s	 and	 Maeda’s	 et	 al	 (107,	 108).	 The	conflicting	 results	 in	 Jakobsen’s	 study	 (109)	might	be	 explained	by	 the	statistical	approach	since	the	results	were	neither	adjusted	for	excessive	bleeding,	 nor	 transfusion	 requirements.	 In	 study	 III	 we	 adjusted	 for	transfusion	requirements	while	the	study	by	Fassl	et	al	adjusted	for	the	number	of	transfused	blood	products	and	incidence	of	major	bleeding.		It	
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is	clear	from	our	analyses	that	the	unadjusted	mortality	and	the	incidence	of	 thromboembolic	 events	 and	death	were	 higher	 in	 patients	who	 had	received	fibrinogen	concentrate.	The	difference	between	the	two	groups	ceased	 when	 a	 multivariable	 analysis	 was	 done.	 The	 present	 results	suggest	 that	 the	 higher	 unadjusted	 incidence	 of	 mortality	 and	thromboembolic	 complications	 which	 was	 found	 in	 fibrinogen	 treated	patients	 are	 likely	 explained	 by	 bleeding	 complications	 and	not	 by	 the	actual	fibrinogen	administration	per	se.			
5.4 EFFECTS OF TRANEXAMIC ACID AND 
FIBRINOGEN CONCENTRATE (IV) Little	is	known	about	the	potential	combined	effect	of	TXA	and	fibrinogen	on	hemostasis	and	bleeding	 in	 cardiac	 surgery.	Based	on	 a	previous	 in	vitro	 study	 by	 He	 et	 al	 (129)	 in	 which	 fibrinogen	 supplementation	combined	with	TXA	counteracted	fibrinolysis	in	platelet	poor	plasma,	we	investigated	 if	 the	 global	 hemostatic	 effects	 of	 fibrinogen	 concentrate	analyzed	by	thromboelastometry	were	further	enhanced	in	the	presence	of	 TXA.	 The	 study	 was	 conducted	 using	 blood	 samples	 from	 cardiac	surgery	patients.	 In	contrast	 to	our	hypothesis,	we	did	not	observe	any	additional	 effects	 on	 clot	 stability	 in	 the	 presence	 of	 TXA.	 Fibrinogen	supplementation,	both	with	and	without	TXA,	had	a	significant	effect	on	both	clotting	time	and	clot	stability.	One	reason	might	be	that	the	present	study	 was	 conducted	 on	 whole	 blood	 with	 cardiovascular	 disease	compared	to	platelet	poor	plasma	from	healthy	donors	in	the	study	by	He	et	 al.	 The	 effect	 of	 patient’s	 preoperative	medication	 such	 as	 ASA	 and	different	analyzing	methods	may		also	be	contributing	factors.		Improved	 hemostasis	 after	 fibrinogen	 supplementation	 has	 previously	been	 demonstrated	 in	 a	 study	 by	 our	 group,	where	 in	 vitro	 fibrinogen	administration	improved	clotting	time	and	clot	stability	in	blood	samples	from	cardiac	surgery	patients	(130).	This	indicates	that	fibrinogen	per	se	has	a	more	pronounced	effect	on	clot	stability	compared	 to	TXA,	which	would	be	expected	given	the	different	roles	of	fibrinogen	and	TXA	in	the	coagulation	process.	Fibrinogen	has	a	central	 role	in	 the	 formation	of	a	clot	and	substitution	of	this	to	diluted	blood	may	therefore	stimulate	both	clot	formation	and	clot	stability	(131,	132).	In	comparison,	TXA	reduces	fibrin	degradation	and	has	in	theory	no	effect	on	the	actual	formation	of	the	clot	(133).		
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TXA	as	an	anti-fibrinolytic	drug	is	used	worldwide	during	cardiac	surgery	to	reduce	bleeding	and	transfusion	requirements	(81,	134).	Fibrinogen	is	increasingly	used	to	treat	ongoing	bleeding	among	these	patients,	based	on	 studies	 indicating	 that	 fibrinogen	 concentrate	 can	 reduce	 bleeding	caused	 by	 low	 fibrinogen	 levels,	 hemodilution	 and	 thrombocytopenia	(131,	132).		In	theory,	there	is	a	potential	risk	that	the	combination	of	TXA,	which	 inhibits	 fibrin	 degradation,	 and	 fibrinogen	 concentrate	might	 be	thromboembolic.	 The	 results	 from	He	 et	 al	might	 suggest	 this,	 but	 the	results	from	the	present	study	do	not.	Larger	in	vivo	studies	analyzing	the	combined	effect	of	TXA	and	fibrinogen	in	a	clinical	setting	could	answer	if	there	is	any	significant	clinical	effect.			
5.5 LIMITATIONS All	 four	 studies	 were	 carried	 out	 in	 a	 single	 center	 which	 raises	 the	question	about	generalizability.		Clinical	parameters	such	as	transfusion	guidelines,	 discontinuation	 of	 anticoagulation	 and	 perioperative	 drugs	may	 vary	 between	 different	 institutions.	 Study	 I	 and	 III	 were	 both	observational	 studies	 and	 there	 may	 be	 inherent	 limitations	 such	 as	unrecorded	confounding	factors	and	selection	bias.	In	 study	 I	 and	 II,	 postoperative	 bleeding	 volume	 was	 the	 primary	endpoint.	Bleeding	volume	is	not	an	ideal	endpoint	since	there	are	several	factors	 apart	 from	 coagulation	 status	 that	 influence	 postoperative	bleeding.	 Also,	 unknown	 confounding	 factors	 related	 to	 surgery	 and	postoperative	intensive	care	might	have	an	impact	on	the	results.	Despite	the	 use	 of	 postoperative	 drainage	 with	 container,	 estimated	 bleeding	volume	 remains	 an	 inconstant	 measurement.	 Although	 other	 more	clinically	 relevant	 endpoints	 such	 as	morbidity	 and	mortality	 could	 be	more	 preferable,	 this	 would	 necessitate	 considerably	 larger	 study	populations.	 Several	 of	 the	 variables	 predicting	 transfusion	 were	 also	related	to	postoperative	bleeding	volume	and	low	fibrinogen	levels,	which	may	obscure	the	statistical	analyses.		In	study	II,	21%	of	the	patients	received	fibrinogen	concentrate	outside	the	study	protocol	which	is	unusually	high	for	routine	CABG	surgery	with	low	expected	bleeding	volume.	An	explanation	may	be	that	the	included	patients	 did	 not	 receive	 TXA	 due	 to	 a	 theoretical	 risk	 of	 increased	thromboembolic	complications	when	administrating	TXA	combined	with	prophylactic	 fibrinogen	concentrate.	The	patients	 in	study	 II	also	had	a	
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significantly	larger	than	normal	postoperative	bleeding	volume	(690	ml	vs	470	ml)	compared	to	previously	reported	bleeding	volume	in	Study	I,	which	might	be	explained	by	the	lack	of	TXA.	Due	to	low	inclusion	rate,	study	II	was	stopped	prematurely	after		three	years.	A	total	of	48	patients	were	analyzed	instead	of	50,	which	was	less	than	the	power	calculation	implied	 to	 prove	 significance.	 This	 may	 in	 theory	 cause	 a	 risk	 of	 a	statistical	type	2	error.		Study	 III	 was	 a	 retrospective	 study.	 The	 indication	 for	 administering	fibrinogen	may	differ	between	treating	physicians.	Neither	was	it	possible	to	collect	reliable	information	about	perioperative	myocardial	infarctions	from	 the	 registries.	 This	potential	 side	 effect	 of	 fibrinogen	 concentrate	administration	could	therefore	not	be	analyzed.	On	the	other	hand,	this	is	the	 largest	 cohort	 study	 so	 far	 analyzing	 the	 effects	 of	 fibrinogen	concentrate	administration	and	potential	thromboembolic	complications	and	death.	Furthermore,	the	registries	used,	NPR	and	SWEDEHEART	have	high	validity	and	are	carefully	monitored	(111,	112,	135).		A	prospective	randomized	 controlled	 study	 evaluating	 fibrinogen	 concentrate	 in	 the	setting	 of	 postoperative	 bleeding	 and	 using	 thromboembolic	complications	as	 endpoint	would	be	more	 ideal,	 but	might	be	 ethically	questionable	given	the	known	effect	of	fibrinogen	on	hemostasis	and	the	lack	of	side	effect	in	study	III	and	other	studies	(107,	108).		As	study	IV	was	an	in	vitro	study,	there	is	indeed	the	question	to	which	extent	 the	 results	 are	 applicable	 in	 the	 clinical	 setting.	Thromboelastometry	on	whole	blood	was	used	to	measure	clot	formation	and	clot	lysis,	but	the	potential	interactions	of	blood	vessels	and	vascular	endothelium	 are	 lacking.	 Also,	 the	 analyses	 were	 performed	 on	 blood	samples	 from	patients	without	ongoing	excessive	bleeding	and	without	fibrinolysis.	The	results	may	not	be	applicable	to	cardiac	surgery	patients	with	ongoing	bleeding	and/or	fibrinolysis.	In	addition,	only	the	FIBTEM-test	 was	 performed,	 and	 fibrinolysis	 was	 only	 assessed	 by	 measuring	maximum	 clot	 lysis.	 These	 are	 both	 selected	 analyses	 which	 display	coagulation	in	part	and	not	the	global	hemostasis	in	the	patient.		
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6 CONCLUSIONS I. Preoperative	plasma	concentration	of	less	than	2.5	g/L	is	independently	 associated	 with	 increased	 postoperative	bleeding.	Preoperative	fibrinogen	concentration	was	not	associated	with	RBC	transfusion.			II. Preoperative	 supplementation	 with	 fibrinogen	concentrate	 did	 not	 reduce	 postoperative	 bleeding	 in	CABG	 patients	 with	 low	 risk	 of	 bleeding	 and	 normal	preoperative	fibrinogen	concentration.			III. There	 was	 no	 increased	 risk	 of	 thromboembolic	complications	 or	 death	 in	 patients	 who	 had	 received	perioperative	administration	of	fibrinogen	concentrate.		IV. The	 enhancing	 effects	 of	 fibrinogen	 on	 clot	 firmness	 in	blood	 samples	 from	 cardiac	 surgery	 patients	 are	 not	further	increased	in	the	presence	of	tranexamic	acid.			
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7 FUTURE PERSPECTIVES Bleeding	 and	 related	 complications	 will	 most	 probably	 remain	 an	important	 issue	 in	 cardiac	 surgery.	 The	 quest	 to	 find	 new	methods	 to	prevent	 and	 handle	 excessive	 bleeding	 will	 continue.	 Strategies	 can	include	 less	 invasive	 surgical	 methods,	 new	 treatments	 to	 enhance	hemostasis	in	case	of	bleeding	and	improved	monitoring	of	perioperative	hemostasis.	Identifying	risk	factors	for	bleeding	in	cardiac	surgery	is	and	will	 be	 an	 ongoing	 process.	 In	 this	 thesis,	 the	 preoperative	 fibrinogen	concentration	 is	 identified	 as	 a	 risk	 factor	 for	 excessive	 bleeding	 after	cardiac	surgery,	although,	the	relative	importance	is	difficult	to	evaluate.		Other	risk	factors	are	probably	more	important.	Preoperative	fibrinogen	concentration	may	therefore	be	one	among	many	other	factors	to	consider	in	a	preoperative	risk	evaluation.		The	use	of	fibrinogen	concentrate	has	become	an	established	method	to	restore	and	improve	hemostasis	in	case	of	acquired	hypofibrinogenemia	due	to	excessive	bleeding.	Despite	this,	the	use	of	fibrinogen	concentrate	in	 this	 setting	 is	 in	 most	 countries	 off-label.	 In	 contrast,	 prophylactic	administration	 of	 fibrinogen	 concentrate	 in	 the	 absence	 of	 ongoing	bleeding,	 especially	 in	 low	 risk	 procedures,	 seems	 not	 to	 be	 of	 value.	Larger,	randomized	studies	would	be	needed	to	determine	the	feasibility	of	prophylactic	 fibrinogen	concentrate	 to	reduce	bleeding	and	need	 for	blood	 transfusion	 in	 complex,	 high	 risk	 surgery.	 Also,	 the	 timing	 and	dosage	of	fibrinogen	administration	would	need	to	be	defined.		The	 safety	 of	 fibrinogen	 use	 has	 now	 been	 reported	 in	 several	 studies	including	 the	 present	 study.	 Despite	 this,	 little	 is	 known	 about	 the	relationship	between	the	actual	dose	administered	to	the	patient,	efficacy	and	 risk	of	 thromboembolic	 complications.	 It	 is	 in	 theory	possible	 that	larger	doses	of	fibrinogen	concentrate	may	be	harmful,	and	the	exact	dose	in	relation	to	the	patient’s	bodyweight	and	gender	is	not	known.		We	found	that	a	combination	of	TXA	and	fibrinogen	concentrate	had	no	additive	 effect	 compared	 to	 fibrinogen	 alone	 on	 clotting	 time	 and	 clot	strength	when	analyzed	in	vitro.	It	may	be	of	interest	to	conduct	a	trial	on	cardiac	 surgery	 patients	 with	 ongoing	 bleeding	 since	 this	 would	 add	information	 about	 the	 importance	 of	 these	 factors	 to	 reduce	 bleeding.	There	are	also	gaps	in	the	evidence	regarding	how	fibrinogen	concentrate	interacts	with	already	circulating	TXA	in	vivo.		
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